Conduit Pharmaceuticals Stock (NASDAQ: CDTTW)

Conduit Pharmaceuticals (NASDAQ:CDTTW) Stock, Quote.Headers.trade-ideas

Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being, prioritized by leading biopharmaceutical companies in order to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready in autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.

Conduit Pharmaceuticals Inc

Looking into the current session, IES Hldgs Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IESC#NASDAQ">IESC</a>) shares are trading at $267.10, after a 5.09% drop. Over the past month, the stock fell by 6.46%, but over the past year, it actually spiked by 221.81%. With questionable short-term performance like this, and great long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio. 

<img src="https://www.benzinga.com/files/images/story/2024/1733508926_0.png" alt="Past Year Chart" />

<h3>IES Hldgs P/E Ratio Analysis in Relation to Industry Peers</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
IES Hldgs has a lower P/E than the aggregate P/E of 55.48 of the Construction &amp; Engineering industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1733508926_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

News

Intraday Update

Markets

IESC

P/E Ratio Insights for IES Hldgs

Shaquille O&#8217;Neal is known for many things – NBA legend, charismatic TV personality, business mogul and an all-around big personality. But even Shaq, with his massive success, didn&#8217;t always have it all figured out, especially when investing his money. In a 2020 Forbes interview, he admitted he used to invest blindly and, as he puts it, &#8220;I would lose almost every time.&#8221; It wasn&#8217;t until a fateful meeting with <a href="https://www.benzinga.com/news/24/11/42254596/jeff-bezos-acts-like-he-owns-the-elite-neighborhood-he-lives-in-but-residents-say-hes-not-much-of-a-neighbor">Jeff Bezos</a> that Shaq&#8217;s entire approach to money changed.
Don't Miss:
<ul>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
<li>It&#8217;s no wonder Jeff Bezos holds over $70 million in art — <a href="https://www.benzinga.com/money/masterworks">this alternative asset has outpaced the S&amp;P 500 since 1995, delivering an average annual return of 11.4%. Here&#8217;s how everyday investors are getting started.</a></li>
</ul>
<h2 class="wp-block-heading">Learning the Hard Way</h2>
When Shaq started making big money from his basketball career and endorsements, he thought investing was simple. <a href="https://www.benzinga.com/startups/24/10/41416630/he-taught-me-a-word-i-never-heard-says-shaquille-oneal-about-the-time-he-received-the-greatest-inves">You put money in and it should grow – </a>right? But it didn&#8217;t always go that way for Shaq. &#8220;When I first started investing, it was all for monetary purposes only. You could tell me anything and if it sounded good, I would invest,&#8221; he said. The result? Losses.&nbsp;
Shaq was open about his early mistakes, sharing that his motivation was simply to make more money without understanding what he was getting into. He was taking chances on anything that sounded promising, but his investments frequently failed because he lacked a solid plan.
See Also: The global games market is projected to generate $272B by the end of the year —<a href="https://www.benzinga.com/money/gameflip"> for $0.55/share, this VC-backed startup with a 7M+ userbase gives investors easy access to this asset market.</a>
Everything changed after a conversation with Jeff Bezos at CES in Las Vegas. Shaq described meeting this &#8220;young, beautiful man&#8221; as a turning point in his financial journey. Bezos told Shaq that most businesses are moving online and that &#8220;he invests in things that are going to change peoples' lives.&#8221; This advice completely reshaped how Shaq approached his money. &#8220;He explained what the future holds,&#8221; Shaq recalled.
After that meeting, Shaq started looking at his investments differently. He asked himself a crucial question: Is this going to help people in their lives? If the answer was yes, he invested. One of his most notable <a href="https://www.benzinga.com/startups/24/09/40677330/shaq-refused-to-pay-80-000-for-security-and-made-a-surprising-choice-he-invested-in-a-company-bezos">investments was in Ring</a>, the home security company. &#8220;I liked what they were doing because everybody wants affordable home security that makes them feel like a trillionaire,&#8221; he said. It also worked for people and he liked that.
Trending: If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/money/arrived-private-credit-fund">7-9% target yield with monthly dividends would you invest in it</a>?
This shift in mindset has paid off for Shaq financially and personally. <a href="https://www.benzinga.com/personal-finance/24/11/41869301/shaqs-got-a-500-million-fortune-but-his-kids-arent-getting-a-dime-without-earning-it-you-need-3-degrees-to-touch-daddys-cheese">His holdings</a> span various industries, including esports, tech, food and real estate. More significantly, though, he takes pride in that his investments are positively impacting.
&#8220;People look at me and say that I'm successful, but I'm not the guy who has all the answers in business,&#8221; Shaq said.
Read Next:
<ul>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Last Chance to get 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
<li>This Jeff Bezos-backed startup will allow you to <a href="https://www.benzinga.com/money/bezos-landlord-100-dollars">become a landlord in just 10 minutes, with minimum investments as low as $100 for properties like the Byer House from Stranger Things.</a></li>
</ul>

Startups

'I Would Lose Almost Every Time' – Shaq Admits He Invested His Money Blindly Before Meeting Jeff Bezos–'He Explained What The Future Holds'

On Thursday, Duality Biologics revealed the first data from a global Phase 1/2a trial of BNT324/DB-1311, which it co-developed with BioNTech SE&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>).
The data were presented in an oral session at the 2024 European Society of Medical Oncology Asia Annual Meeting in&nbsp;Singapore&nbsp;and showed encouraging antitumor activity alongside a manageable safety profile in heavily pretreated patients with locally advanced or <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/n42356375/duality-biologics-and-biontech-presented-positive-interim-data-for-investigational-b7-h3-antibody-" rel="noreferrer noopener">metastatic solid tumors</a>.
The ongoing Phase 1/2a trial analysis included 277 participants across various solid tumor types.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41949384/biontech-boosts-oncology-strategy-with-800-million-china-based-biotheus-acquisition" rel="noreferrer noopener">BioNTech Boosts Oncology Strategy With $800 Million+ China-Based Biotheus Acquisition</a>
The trial&#8217;s primary endpoints are safety and an objective response rate. The secondary endpoints include duration of response, disease control rate, progression-free survival, and overall survival.
The data showed the following results: Among all evaluable patients with at least one post-baseline tumor assessment (n=238), the overall unconfirmed objective response rate (uORR) was 32.4%, and the disease control rate (DCR) was 82.4%.
Among patients with small cell lung cancer (n=73), the uORR was 56.2%, and the DCR was 89.0%.
Most small cell lung cancer patients received 6 mg/kg and 9 mg/kg of BNT324/DB-1311, with no difference in uORR between the two dose groups (54.5% and 58.8%, respectively).
Notably, at the 9 mg/kg dose level, the uORR in patients with small cell lung cancer who had prior immunotherapy but no treatment with topoisomerase I inhibitors reached 70.4%.
Most patients with non-small cell lung cancer had non-squamous histology (n=41), exhibiting an uORR of 22.0%, while patients with squamous non-small cell lung cancer (n=25) had an uORR of 16.0%.
Among patients with castration-resistant prostate cancer (n=32), BNT324/DB-1311 demonstrated early antitumor activity with an uORR of 28.0% and a DCR of 92.0%.
The imaging progression-free survival (rPFS) data were not mature at the time of the analysis, with a median rPFS of 7.2 months. The 6-month rPFS rate was 94.7%.
In other tumor types, including cervical cancer (n=4), hepatocellular carcinoma (n=12), head and neck squamous carcinoma (n=3), and melanoma (n=11), BNT324/DB-1311 also exhibited antitumor activity with uORRs of 75.0%, 25.0%, 100.0%, and 36.4%, respectively.
BNT324/DB-1311 showed a manageable safety profile across all evaluated patients and tumor types.
BNT324/DB-1311 is one of three clinical-stage ADC candidates in BioNTech&#8217;s and DualityBio&#8217;s global strategic partnership.
Multiple clinical trials combining selected assets from BioNTech&#8217;s and DualityBio&#8217;s strategic partnership are planned for various solid tumor indications.
Price Action: BNTX stock is up 3.01% at $122.42&nbsp;at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42366347/taiwan-semi-set-to-power-taiwan-semiconductor-index-surge-in-2025-fueled-by-ai-demand" target="_blank" rel="noreferrer noopener">Chipmaker Taiwan Semiconductor Should See Business Grow 20% Fueled By AI Demand: Analyst</a></li>
</ul>

Biotech

Large Cap

Health Care

Movers

Trading Ideas

General

BNTX

Why Is BioNTech Stock Trading Higher On Friday?

Dollar General Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>) reported downbeat earnings for its third <a href="https://www.benzinga.com/quote/dg/earnings">quarter on Thursday</a>.
The company posted third-quarter adjusted EPS of 89 cents, down 29.4% year-over-year, missing the consensus of 94 cents. The retail behemoth reported quarterly sales of $10.2 billion, slightly above the consensus of $10.14 billion.
&#8220;We are pleased with our team&#8217;s execution in the third quarter, particularly in light of multiple hurricanes that impacted our business,&#8221; said Todd Vasos, Dollar General&#8217;s chief executive officer. &#8220;While we continue to operate in an environment where our core customer is financially constrained, we delivered same-store sales near the top end of our expectations for the quarter.&#8221;
Dollar General updated its financial guidance, including the negative impact of hurricane-related expenses of $32.7 million in the third quarter and an estimated fourth-quarter negative impact of approximately $10 million.
The company expects 2024 net sales growth of approximately 4.8% to 5.1%, compared to its previous expectation of roughly 4.7% to 5.3%.
Dollar General shares gained 3.1% to trade at $82.03 on Friday.
These analysts made changes to their price targets on Dollar General following earnings announcement.
<ul>
<li>Truist Securities analyst Scot Ciccarelli maintained Dollar General with a Hold and lowered the price target from $94 to $83.</li>
<li>Goldman Sachs analyst Kate McShane maintained the stock with a Buy and lowered the price target from $122 to $104.</li>
<li>BMO Capital analyst Kelly Bania maintained the stock with a Market Perform and raised the price target from $80 to $84.</li>
<li>Evercore ISI Group analyst Michael Montani maintained the stock with an In-Line and increased the price target from $95 to $96</li>
</ul>
Considering buying DG stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="440" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/06131247/Screenshot-2024-12-06-234230-1024x440.png" alt="" class="wp-image-681123" style="width:547px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/06131247/Screenshot-2024-12-06-234230-1024x440.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/06131247/Screenshot-2024-12-06-234230-300x129.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/06131247/Screenshot-2024-12-06-234230-768x330.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/06131247/Screenshot-2024-12-06-234230.png 1437w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/12/42364367/how-to-earn-500-a-month-from-oracle-stock-ahead-of-q2-earnings">How To Earn $500 A Month From Oracle Stock Ahead Of Q2 Earnings</a></li>
</ul>

Earnings

Price Target

Analyst Ratings

These Analysts Revise Their Forecasts On Dollar General Following Q3 Results

On Friday, Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) revealed topline results from the APPULSE-PNH Phase 3B study of Fabhalta&nbsp;(iptacopan) in adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who were switched from anti-C5 therapies (Hb ≥10g/dL following treatment with eculizumab or ravulizumab).
Ultomiris (ravulizumab) and Soliris&nbsp;(eculizumab) are commonly used anti-C5 therapies, and they are made by AstraZeneca Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>).
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41634528/positive-outlook-for-novartis-as-company-capitalizes-on-growing-treatment-opportuni" rel="noreferrer noopener">Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights</a>
PNH is a rare complement-mediated blood disorder. People with PNH have an acquired mutation in some of their hematopoietic stem cells, which are located in the bone marrow and can grow and develop into red blood cells, white blood cells, and platelets.
This mutation <a target="_blank" href="https://www.novartis.com/news/media-releases/new-phase-iiib-data-shows-novartis-fabhalta-improved-hemoglobin-levels-adult-patients-paroxysmal-nocturnal-hemoglobinuria-who-switched-from-anti-c5-therapy" rel="noreferrer noopener">causes</a> them to produce RBCs that are susceptible to premature destruction by the complement system.
After 24 weeks of treatment with Fabhalta, the average hemoglobin (Hb) level improved compared to baseline. The study&#8217;s safety profile of Fabhalta monotherapy was consistent with previously reported data.
Data will be presented at an upcoming medical meeting in 2025.
The FDA recently granted accelerated approval for Fabhalta to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, and development is ongoing in multiple complement-mediated diseases.
Last month, Novartis raised its mid-term sales guidance, increasing its compound annual growth rate (CAGR) target to 6% from 5% <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/42115127/novartis-confident-in-growth-as-it-elevates-midterm-sales-forecast-ceo-narasimhan-highlights-robust-pipeline-supporting-long-term-strategy" rel="noreferrer noopener">for 2023-2028</a>.
The upgrade reflects performance from current growth drivers and anticipated launches, many of which are expected to retain U.S. exclusivity into the 2030s.
Earlier this week, PTC Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) signed an exclusive global license and collaboration agreement with&nbsp;Novartis for its PTC518 Huntington&#8217;s disease program, which&nbsp;<a target="_blank" href="https://www.benzinga.com/24/12/42272846/ptc-therapeutics-inks-licensing-pact-with-novartis-worth-3-billion-for-huntingtons-program" rel="noreferrer noopener">includes related molecules</a>.
Under the agreement, PTC will receive an upfront payment of $1.0 billion, up to $1.9 billion in development, regulatory and sales milestones, a profit share in the U.S., and double-digit tiered royalties on ex-U.S. sales.
<h2 class="wp-block-heading">Is Novartis A Good Stock To Buy?</h2>
Wall Street analysts view Novartis on the whole as a Neutral, given the history of coverage over the past three months. Graham Perry from B of A Securities in Novartis is the most bearish, expecting a 3.7% fall in the stock in the coming year.
But looking at how the market as a whole thinks of the stock, you can reference historical price action for views on whether investors feel strongly about the stock one way or another. In the past 3 months, Novartis fell 12.4%, which indicates that opinion soured on the business and how attractive it is to own based on either its stock price, or underlying fundamentals, like revenue, which rose 8.84% over the past year.
A complete overview of how Wall Street views individual stocks is available <a href="https://www.benzinga.com/analyst-stock-ratings">here</a>, while real time updates on the latest analyst actions will be delivered via <a href="https://pro.benzinga.com">Benzinga PRO</a>. Try it for free.
Price Action: At the last check on Friday, NVS stock was up 0.18% to $102.34.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42359798/asia-markets-mixed-europe-advances-oil-slides-while-gold-and-dollar-strengthen-global-markets-today-while-us-slept" target="_blank" rel="noreferrer noopener">China And Europe Markets Advance, Gold And Dollar Tick Higher &#8211; Global Markets Today While US Slept</a></li>
</ul>
Photo by Taljat David via Shutterstock

PTCT

Novartis Touts Encouraging Data From Late-Stage Study For Fabhalta In Rare Type Of Blood Disorder

Petco Health and Wellness Company, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WOOF#NASDAQ">WOOF</a>) reported better-than-expected results for its <a href="https://www.benzinga.com/quote/WOOF/earnings">third quarter on Thursday.</a>
The company posted a quarterly loss of 1 cents per share versus market estimates of a loss of 4 cents per share. The company reported quarterly sales of $1.51 billion which beat the analyst consensus estimate of $1.50 billion.
&#8220;Our third quarter results demonstrate the meaningful progress we&#8217;re making to strengthen our retail fundamentals to drive sustainable, profitable growth,&#8221; said Joel Anderson, Petco&#8217;s Chief Executive Officer. &#8220;While there is more work to do, our improving results increase our conviction that we are on the right path to position Petco to win long-term. Our entire organization is focused on driving profitability and free cash flow, and I&#8217;m confident we&#8217;re set up for a solid finish to 2024.&#8221;
Petco Health shares gained 16.9% to trade at $5.73 on Friday.
These analysts made changes to their price targets on Petco Health following earnings announcement.
<ul>
<li>Wells Fargo analyst Zachary Fadem maintained Petco Health and Wellness with an Equal-Weight and raised the price target from $3 to $5.</li>
<li>RBC Capital analyst Steven Shemesh maintained the stock with an Outperform and boosted the price target from $5 to $6.</li>
<li>Morgan Stanley analyst Simeon Gutman maintained Petco Health and Wellness with an Equal-Weight and raised the price target from $3 to $6.</li>
<li>Wedbush analyst Seth Basham maintained Petco Health and Wellness with an Outperform and boosted the price target from $5.5 to $6.</li>
</ul>
Considering buying WOOF stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="567" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/06130514/Screenshot-2024-12-06-233454-1024x567.png" alt="" class="wp-image-681107" style="width:571px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/06130514/Screenshot-2024-12-06-233454-1024x567.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/06130514/Screenshot-2024-12-06-233454-300x166.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/06130514/Screenshot-2024-12-06-233454-768x426.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/06130514/Screenshot-2024-12-06-233454.png 1173w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/12/42364367/how-to-earn-500-a-month-from-oracle-stock-ahead-of-q2-earnings">How To Earn $500 A Month From Oracle Stock Ahead Of Q2 Earnings</a></li>
</ul>

WOOF

These Analysts Increase Their Forecasts On Petco Health and Wellness After Strong Q3 Results

Legal

CTLT

EU Regulators Say Novo Holdings Secures Unconditional EU Antitrust Approval For $16.5B Catalent Deal

<a href="https://www.chicagofed.org/events/2024/economic-outlook-symposium" title="https://www.chicagofed.org/events/2024/economic-outlook-symposium">https://www.chicagofed.org/events/2024/economic-outlook-symposium</a> &nbsp;

Federal Reserve

Fed's Goolsbee Says The Outlook Does Matter, So When The New Administration Starts Proposing Policies The Fed Will Start To Think Through It; A Single Month's Data Is Not Reliable, But If Household Survey Were To Show Steady Deterioration Fed Would Have To Look At It More Closely

Evercore ISI Group analyst Kirk Materne maintains Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) with a In-Line and raises the price target from $220 to $245.

VEEV

Evercore ISI Group Maintains In-Line on Veeva Systems, Raises Price Target to $245

Feds Goolsbee Says Economic Conditions Will Determine The Pace Of Rate Cuts From Here; The Speed At Which The Fed Is Moving Will Probably Slow As Debate Proceeds On A Stopping Point; Will Be Watching Interest Rate Sensitive Sectors, Lagged Impact Of Monetary Policy, For Signs That Neutral Rate Is Approaching; Likely That Goods Prices Will Return To Deflation, Services Continues In The Right Direction, Market Data On Housing Suggests Coming Improvement There

Fed's Goolsbee Says Tariffs Raise Prices, But Would Not Result In Persistent Inflation Unless There Is Retaliation From Other Countries Or Impacts On The Supply Chain; On Tariffs On Canada And Mexico -- Implications For Chicago Region Could Be More Difficult Since Many Imports Are Intermediate Goods For Other Products; An Issue On The Minds Of Regional Business; A Gradual Pace Of Rate Cuts Seems Appropriate; Hope The Fed Will Get Close To The Range Of Neutral By The End Of 2025

Genesco Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GCO#NYSE">GCO</a>) shares are <a target="_blank" href="https://www.benzinga.com/movers" rel="noreferrer noopener">trading higher on Friday</a> after the company reported third-quarter financial results. It clocked an adjusted earnings per share of 61 cents, <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42360590/genesco-inc-reports-fiscal-2025-third-quarter-results" rel="noreferrer noopener">beating the street view of 29 cents</a>. Quarterly revenues of $596.328 million (+3%) beat the analyst consensus estimate of $577.93 million.
Comparable sales rose 6%, with e-commerce sales up 15% and store sales increasing 4%. E-commerce accounted for 24% of retail sales.
&#8220;This result was driven by the initial phase of Journeys&#8217; strategic growth plan which has focused on elevating the consumer experience including improving the product assortment and visually resetting our stores,&#8221; said Mimi E. Vaughn, Genesco&#8217;s Board Chair.
The overall sales increase for the third quarter was driven by an increase of 4% at Journeys, an increase of 3% at Schuh and a 10% increase at Genesco Brands, partially offset by a decrease of 4% at Johnston &amp; Murphy.&nbsp;
Also Read: <a target="_blank" href="https://www.benzinga.com/news/econ-s/24/12/42366245/consumer-sentiment-hits-7-month-high-but-inflation-fears-divide-democrats-republicans" rel="noreferrer noopener">Consumer Sentiment Hits 7-Month High, But Inflation Fears Divide Democrats, Republicans</a>
Third quarter gross margin decreased 30 basis points to 47.8% compared with 48.1% last year, due primarily to changes in product mix at Journeys.
Genesco held cash and equivalents of $33.6 million as of November 2, compared with $21.7 million in the year-ago period. At the end of the third quarter of fiscal 2025, total debt was $100.1 million.
The company said it closed 12 Journeys stores in the third quarter (for a total of 41 Journeys stores closed to date in Fiscal 2025) and expects to close up to another 10 Journeys stores in Fiscal 2025.
Outlook: Genesco raised its FY25 adjusted EPS forecast to $0.80-$1.00, compared to the analyst estimate of $0.80 (Prior view: $0.60-$1.00).
Genesco now expects total sales to be flat or down 1% compared to Fiscal 2024. Excluding the 53rd week, sales are expected to be flat to up 1%.
Price Action: GCO shares are up 6.50% to $39.84 at the last check on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/12/42363278/us-economy-adds-227000-jobs-in-november-wage-growth-accelerates" target="_blank" rel="noreferrer noopener">US Economy Adds 227,000 Jobs In November, Wage Growth Accelerates</a></li>
</ul>
Photo by JHVEPhoto via Shutterstock

Equities

Guidance

Retail Sales

Why Genesco Stock Is Trading Higher On Friday

Fed's Goolsbee Says For Fed To Change Policy Direction Data Will Need To Show Inflation Is Not Heading To 2% Or Job Market Looks Like The Economy Is Overheating; Housing Inflation Likely To Fall As Lagging Government Data Reflects What Private Data Is Already Showing; If Congress And The President Want To Pass Tariffs, The Fed's Job Is To Respond To Those Conditions

WIIM

DNLI

Denali Therapeutics shares are trading higher. The stock may be moving on continued strength after announcing on Thursday it began its Phase 2a study of LRRK2 Inhibitor BIIB122 for LRRK2-associated parkinson's disease with its first participant dosed.

Macro Economic Events

Econ #s

Economics

U.S. Baker Hughes Oil Rig Count +5 At 482; U.S. Baker Hughes NatGas Rig Count +2 At 102; U.S. Baker Hughes Total Rig Count 589

<a href="https://www.chicagofed.org/events/2024/economic-outlook-symposium" title="https://www.chicagofed.org/events/2024/economic-outlook-symposium">https://www.chicagofed.org/events/2024/economic-outlook-symposium</a>
&nbsp;
&nbsp;
&nbsp;
&nbsp;

Fed's Goolsbee Says Taking The Possibility Seriously That Productivity Improvements May Be Persistent; Trying To Understand The Implications Of A Lasting Productivity Improvement; In Principle, Rising Productivity Is A Way Around Labor Constraints; Behavior Of Labor Market In The Past Few Months Does Look Like It Is Settling Around Full Employment, But Fed Would Still Monitor Closely For Signs Of Deterioration

Investors with a lot of money to spend have taken a bearish stance on Salesforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with CRM, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 36 uncommon options trades for Salesforce.
This isn't normal.
The overall sentiment of these big-money traders is split between 30% bullish and 41%, bearish.
Out of all of the special options we uncovered, 4 are puts, for a total amount of $179,534, and 32 are calls, for a total amount of $1,400,137.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $220.0 to $400.0 for Salesforce over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Salesforce's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Salesforce's significant trades, within a strike price range of $220.0 to $400.0, over the past month.
<h3>Salesforce Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1733508178_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$133.9</td>
<td>$132.65</td>
<td>$133.0</td>
<td>$250.00</td>
<td>$133.0K</td>
<td>595</td>
<td align="right">12</td>
</tr>
<tr>
<td>CRM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/27/24</td>
<td>$11.8</td>
<td>$11.4</td>
<td>$11.8</td>
<td>$360.00</td>
<td>$118.0K</td>
<td>518</td>
<td align="right">207</td>
</tr>
<tr>
<td>CRM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$39.0</td>
<td>$38.6</td>
<td>$39.0</td>
<td>$400.00</td>
<td>$101.4K</td>
<td>1</td>
<td align="right">26</td>
</tr>
<tr>
<td>CRM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/06/24</td>
<td>$25.4</td>
<td>$24.0</td>
<td>$25.4</td>
<td>$340.00</td>
<td>$76.2K</td>
<td>4.6K</td>
<td align="right">45</td>
</tr>
<tr>
<td>CRM</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$30.35</td>
<td>$29.85</td>
<td>$30.11</td>
<td>$360.00</td>
<td>$75.2K</td>
<td>1.0K</td>
<td align="right">26</td>
</tr>
</tbody>
</table>

<h3>About Salesforce</h3>
Salesforce provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Having examined the options trading patterns of Salesforce, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Where Is Salesforce Standing Right Now?</h3>
<ul>
<li>With a trading volume of 2,919,534, the price of CRM is up by 0.31%, reaching $362.51.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 82 days from now.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Salesforce options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Spotlight on Salesforce: Analyzing the Surge in Options Activity

In the preceding three months, 11 analysts have released ratings for Crocs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CROX#NASDAQ">CROX</a>), presenting a wide array of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Crocs and provided 12-month price targets. The average target is $145.45, accompanied by a high estimate of $182.00 and a low estimate of $110.00. Experiencing a 9.47% decline, the current average is now lower than the previous average price target of $160.67. 
<img src="https://www.benzinga.com/files/images/story/2024/1733508176_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Crocs. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Robert Drbul</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Buy</td>
<td>$155.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Tom Nikic</td>
<td>Needham</td>
<td>Announces</td>
<td>Buy</td>
<td>$116.00</td>
<td>-</td>
</tr>
<tr>
<td>Laura Champine</td>
<td>Loop Capital</td>
<td>Lowers</td>
<td>Hold</td>
<td>$110.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Robert Drbul</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$155.00</td>
<td>$182.00</td>
</tr>
<tr>
<td>Laura Champine</td>
<td>Loop Capital</td>
<td>Lowers</td>
<td>Buy</td>
<td>$150.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Ashley Owens</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$150.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Jay Sole</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$122.00</td>
<td>$146.00</td>
</tr>
<tr>
<td>Jonathan Komp</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$180.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Adrienne Yih</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$125.00</td>
<td>$164.00</td>
</tr>
<tr>
<td>Robert Drbul</td>
<td>Guggenheim</td>
<td>Announces</td>
<td>Buy</td>
<td>$182.00</td>
<td>-</td>
</tr>
<tr>
<td>Ashley Owens</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$155.00</td>
<td>$149.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Crocs. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Crocs compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Crocs's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Crocs's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CROX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Crocs analyst ratings.</a>
<h2>All You Need to Know About Crocs</h2>
Crocs Inc is engaged in the design, development, marketing, distribution, and sale of casual lifestyle footwear accessories for men, women, and children. The reportable geographic segments of the company include the Americas, Asia Pacific, and EMEA.
<h3>Crocs: Delving into Financials</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Crocs displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 1.58%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Consumer Discretionary sector.
Net Margin: Crocs's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 18.81%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Crocs's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 11.83%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Crocs's ROA excels beyond industry benchmarks, reaching 4.24%. This signifies efficient management of assets and strong financial health.
Debt Management: With a high debt-to-equity ratio of 1.03, Crocs faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>How Are Analyst Ratings Determined?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CROX

What 11 Analyst Ratings Have To Say About Crocs

Investors with a lot of money to spend have taken a bullish stance on United States Steel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/X#NYSE">X</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with X, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 11 uncommon options trades for United States Steel.
This isn't normal.
The overall sentiment of these big-money traders is split between 54% bullish and 36%, bearish.
Out of all of the special options we uncovered, 5 are puts, for a total amount of $295,011, and 6 are calls, for a total amount of $323,362.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $30.0 to $50.0 for United States Steel over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of United States Steel stands at 13491.44, with a total volume reaching 4,431.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in United States Steel, situated within the strike price corridor from $30.0 to $50.0, throughout the last 30 days.
<h3>United States Steel Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1733508173_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$10.0</td>
<td>$7.25</td>
<td>$8.0</td>
<td>$40.00</td>
<td>$80.0K</td>
<td>24.0K</td>
<td align="right">100</td>
</tr>
<tr>
<td>X</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$8.75</td>
<td>$8.0</td>
<td>$8.74</td>
<td>$37.00</td>
<td>$78.7K</td>
<td>2.4K</td>
<td align="right">615</td>
</tr>
<tr>
<td>X</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$2.92</td>
<td>$1.98</td>
<td>$2.3</td>
<td>$33.00</td>
<td>$74.2K</td>
<td>5</td>
<td align="right">323</td>
</tr>
<tr>
<td>X</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$8.75</td>
<td>$8.0</td>
<td>$8.74</td>
<td>$37.00</td>
<td>$69.8K</td>
<td>2.4K</td>
<td align="right">514</td>
</tr>
<tr>
<td>X</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$5.1</td>
<td>$4.8</td>
<td>$5.1</td>
<td>$38.00</td>
<td>$66.3K</td>
<td>944</td>
<td align="right">108</td>
</tr>
</tbody>
</table>

<h3>About United States Steel</h3>
United States Steel Corp operates primarily in the United States but also has a steelmaking capacity in Slovakia. The company's operating segments include North American Flat-Rolled (Flat-Rolled), Mini Mill, U. S. Steel Europe (USSE), and Tubular Products (Tubular). The Flat-Rolled segment includes U. S. Steel's integrated steel plants and equity investees in North America involved in the production of slabs, strip mill plates, sheets, and tin mill products, as well as all iron ore and coke production facilities in the United States. It primarily serves North American customers in the service center, conversion, transportation, construction, container, and appliance, and electrical markets.
Following our analysis of the options activities associated with United States Steel, we pivot to a closer look at the company's own performance.
<h3>Where Is United States Steel Standing Right Now?</h3>
<ul>
<li>With a volume of 1,932,312, the price of X is down -2.82% at $37.76. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 55 days.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest United States Steel options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Market Whales and Their Recent Bets on United States Steel Options

Financial giants have made a conspicuous bullish move on Toronto-Dominion Bank. Our analysis of options history for Toronto-Dominion Bank (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TD#NYSE">TD</a>) revealed 10 unusual trades.
Delving into the details, we found 50% of traders were bullish, while 30% showed bearish tendencies. Out of all the trades we spotted, 2 were puts, with a value of $67,556, and 8 were calls, valued at $304,678.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $47.5 to $60.0 for Toronto-Dominion Bank over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
In terms of liquidity and interest, the mean open interest for Toronto-Dominion Bank options trades today is 1623.5 with a total volume of 2,091.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Toronto-Dominion Bank's big money trades within a strike price range of $47.5 to $60.0 over the last 30 days.
<h3>Toronto-Dominion Bank Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1733508167_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$3.8</td>
<td>$3.2</td>
<td>$3.8</td>
<td>$60.00</td>
<td>$60.8K</td>
<td>332</td>
<td align="right">20</td>
</tr>
<tr>
<td>TD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$5.4</td>
<td>$4.9</td>
<td>$4.9</td>
<td>$55.00</td>
<td>$59.8K</td>
<td>3.7K</td>
<td align="right">270</td>
</tr>
<tr>
<td>TD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$1.8</td>
<td>$1.6</td>
<td>$1.75</td>
<td>$47.50</td>
<td>$35.0K</td>
<td>29</td>
<td align="right">200</td>
</tr>
<tr>
<td>TD</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$3.6</td>
<td>$3.4</td>
<td>$3.5</td>
<td>$55.00</td>
<td>$35.0K</td>
<td>3.9K</td>
<td align="right">406</td>
</tr>
<tr>
<td>TD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$3.6</td>
<td>$3.1</td>
<td>$3.45</td>
<td>$55.00</td>
<td>$34.5K</td>
<td>3.9K</td>
<td align="right">306</td>
</tr>
</tbody>
</table>

<h3>About Toronto-Dominion Bank</h3>
Toronto-Dominion is one of Canada's two largest banks and operates three business segments: Canadian retail banking, US retail banking, and wholesale banking. The bank's US operations span from Maine to Florida, with a strong presence in the Northeast. It also has a 13% ownership stake in Charles Schwab.
Following our analysis of the options activities associated with Toronto-Dominion Bank, we pivot to a closer look at the company's own performance.
<h3>Current Position of Toronto-Dominion Bank</h3>
<ul>
<li>Currently trading with a volume of 2,800,509, the TD's price is down by -1.63%, now at $51.94. </li>
<li>RSI readings suggest the stock is currently may be oversold.</li>
<li>Anticipated earnings release is in 83 days.</li>
</ul>
<h3>What The Experts Say On Toronto-Dominion Bank</h3>
In the last month, 1 experts released ratings on this stock with an average target price of $77.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from RBC Capital has decided to maintain their Sector Perform rating on Toronto-Dominion Bank, which currently sits at a price target of $77. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Toronto-Dominion Bank with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Decoding Toronto-Dominion Bank's Options Activity: What's the Big Picture?

Conduit Pharmaceuticals: Stellar Management Team, New Business Model

CDTTW

Agilent Technologies

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solns

Bruker

Conduit Pharmaceuticals

Charles River Laboratories International, Inc. Common Stock

Charles River

Cytek Biosciences

Danaher

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

Conduit Pharmaceuticals

Conduit Pharmaceuticals (CDTTW) Forecast

Conduit Pharmaceuticals (NASDAQ:CDTTW) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga